Pacira invests in biopharmaceutical company

Biologics

Pacira Biosciences invested $3 million in Spine BioPharma.

The investment was in the form of a convertible note, according to an April 20 news release. It will support the development of Remedisc, a therapeutic for the treatment of degenerative disc disease.

Pacira plans to make an additional $7 million investment based on future milestones. The investment follows Spine BioPharma's recent series A financing round.

More articles on biologics:
Florida surgeon performs disc replacement on wrong area of patient's spine
2 spine surgeon leaders exit Johns Hopkins
5 high-profile device company court battles: Medtronic, Smith+Nephew & more 

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers